Biodesix Names Kieran O'Kane as Chief Commercial Officer
10 March 2020 - - US-based diagnostic company Biodesix, Inc has promoted Kieran O'Kane to chief commercial officer and Bobbi Coffin, current chief marketing officer, to chief growth officer, effective immediately, the company said.

The is intended to power the company's growth strategy in 2020 and beyond.

Since joining Biodesix in 2018 as Head of Strategic Marketing and Corporate Development, Kieran O'Kane has played a leadership role in establishing Biodesix as a leader in the development of blood-based diagnostic solutions for lung cancer.

During his time with Biodesix, he has led the successful acquisition of Integrated Diagnostics and Oncimmune's laboratory and incidental pulmonology nodule malignancy test, and has subsequently been instrumental in the commercial launch of the Nodify XL2 and Nodify CDT tests.

To drive continued growth across all commercial aspects of its business and industry, Biodesix TODAY also added a new chief growth officer position and named Bobbi Coffin as the inaugural CGO.

Bobbi's extensive diagnostic marketing background and seasoned experience of more than two decades in creating new pathways to growth while optimising resources, maximising the impact of investment, and monitoring future trends make her the ideal professional to lead this function.

Bobbi joined Biodesix in 2015 from Exact Sciences where she was vice president of Commercial Marketing and Strategy.

Prior to that role, Bobbi held leadership positions at Precision Therapeutics and Cytyc/Hologic.

Biodesix is a lung cancer diagnostic solutions company covering the continuum of patient care from early risk classification of lung nodules through treatment guidance in late stage cancer.

The company develops blood-based diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence.

Biodesix is the first company to offer four approved, non-invasive tests for patients with lung cancer or suspicious lung nodules. The Biodesix Lung Reflex strategy for lung cancer patients integrates the GeneStrat and VeriStrat tests to support treatment decisions with results in 72 hours, expediting time to treatment.

The Nodify XL2 test and the Nodify CDT test evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges.